&lt;p&gt;Association of TP53 Mutations with Response to Anlotinib Treatment in Advanced Non-Small Cell Lung Cancer&lt;/p&gt;

Fang, Shencun; Cheng, Wei; Zhang, Meiling; Yang, Rusong

doi:10.2147/ott.s257052

Cited by 9 publications

(8 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The therapeutic effect reached PR and PFS was more than 7 months ( 26 ). The K-RAS mutation status may be an indicator of good response to the PD-1 mAb, the TP53 mutation patients also showed good response to anlotinib ( 27 ). So clinical trial like combination of anlotinib and PD-1 mAb may be promising in patients with K-RAS mutation and TP53 mutation co-existed.…”

Section: Discussionmentioning

confidence: 99%

The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer

et al. 2021

View full text Add to dashboard Cite

BackgroundBoth anlotinib and programmed death 1 (PD-1) monoclonal antibody (mAb) have been approved for the third line treatment of metastatic non-small cell lung cancer (NSCLC). However, the combination of these two standard therapies has not been investigated in third-line or further-line treatment of patients with advanced NSCLC.MethodsWe reviewed 22 patients with NSCLC who received anlotinib combined with PD-1 mAb therapy from July 2018 to October 2019 at Sir Run Run Shaw Hospital. Based on the baseline characteristics, PD-L1 expression and EGFR mutation status, we retrospectively analyzed the efficacy and safety of this combination therapy by RESIST 1.1 and CTCAE 5.0.ResultsThe combination treatment of anlotinib and PD-1 mAb in 22 NSCLC patients gained a median PFS of 6.8 months and a median OS of 17.3 months. The disease control rate (DCR) was 90.9%, and the objective response rate (ORR) was 36.4%, where 1 (4.6%) patient achieved complete response (CR) and 7 (31.8%) patients achieved partial response (PR). The median time to response was 3.9 months, and the median duration of the response was 6.8 months. The common grades 1–2 adverse events were fatigue 10/22 (45.5%), decreased appetite 9/22 (40.9%), hypertension 10/22 (45.5%); the common grades 3–4 adverse events were hypertension 2/22 (9.1%) and mouth ulceration 2/22 (9.1%).ConclusionAnlotinib combined with PD-1 mAb showed promising efficacy in third-line or further-line treatment of NSCLC, and its adverse effects is tolerable.

show abstract

Section: Discussionmentioning

confidence: 99%

The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Therefore, antiangiogenic inhibitors have a therapeutic effect on patients with TP53 mutations [26]. A case report described the favorable response to anlotinib in three patients with advanced NSCLC harboring TP53 mutation [27]. Of course, the above further proved that the patient had a good effect because of the combination of afatinib and anlotinib.…”

Section: Discussionmentioning

confidence: 98%

Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature

et al. 2021

World J Surg Onc

View full text Add to dashboard Cite

Background HER2 is a member of the ERBB family of receptor tyrosine kinases, and HER2 mutations occur in 1–4% of non-small cell lung cancer (NSCLC) as an oncogenic driver mutation. We found a rare mutation of HER2 p.Asp769Tyr in NSCLC. Case presentation We presented a case of a 68-year-old nonsmoking male patient with brain metastasis from lung adenocarcinoma harboring a rare mutation of HER2 p.Asp769Tyr. After multiple lines of treatment, he obtained a durable response (10 months) to afatinib and anlotinib. Conclusion We reported for the first time that afatinib and anlotinib have successfully treated lung adenocarcinoma with HER2 p.Asp769Tyr mutation. This finding can provide an insight into the optimal treatment of lung adenocarcinoma patients with novel mutations. Additionally, we summarized the efficacy of targeted therapy for HER2 mutant lung cancer in this article.

show abstract

“…Recently, Onco Targets and Therapy reported three advanced lung cancer patients with TP53 mutations, which responded well to anlotinib. 18 Other authors also reported the role of the Tp53 protein in inhibiting angiogenesis and angiogenesis. 19 , 20 This is consistent with some previous reports that TP53 mutations are sensitive to angiogenesis, suggesting that patients with Tp53 mutations may be a potential benefit group for anlotinib.…”

Section: Discussionmentioning

confidence: 98%

A Case Report of Targeted Therapy with Anlotinib in a Patient with Advanced Breast Metaplastic Carcinoma

Zou¹,

Xiao²,

Duan³

et al. 2021

OTT

View full text Add to dashboard Cite

<p>Association of TP53 Mutations with Response to Anlotinib Treatment in Advanced Non-Small Cell Lung Cancer</p>

Cited by 9 publications

References 17 publications

The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer

The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer

Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature

A Case Report of Targeted Therapy with Anlotinib in a Patient with Advanced Breast Metaplastic Carcinoma

Contact Info

Product

Resources

About